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Hemophilia A, a life-threatening bleeding disorder, is caused by deficiency of factor VIII (FVIII). Replacement therapy using rFVIII is the first
line therapy for hemophilia A. However, 15–30% of patients develop neutralizing antibody, mainly against the C2, A3 and A2 domains. It has been
reported that PS-FVIII complex reduced total and neutralizing anti-rFVIII antibody titers in hemophilia Amurine models. Here, we developed FVIII-
containing cochleate cylinders, utilizing PS-Ca2+ interactions and characterized these particles for optimal in vivo properties using biophysical and
biochemical techniques. Approximately 75% of the protein was associated with cochleate cylinders. Sandwich ELISA, acrylamide quenching and
enzymatic digestion studies established that rFVIII was shielded from the bulk aqueous phase by the lipidic structures, possibly leading to improved
in vivo stability. Freeze–thawing and rate-limiting diffusion studies revealed that small cochleate cylinders with a particle size of 500 nm or less could
be generated. The release kinetics and in vivo experiments suggested that there is slow and sustained release of FVIII from the complex upon systemic
exposure. In vivo studies using tail clip method indicated that FVIII–cochleate complex is effective and protects hemophilic mice from bleeding.
Based on these studies, we speculate that the molecular interaction between FVIII and PS may provide a basis for the design of novel FVIII lipidic
structures for delivery applications.
© 2007 Elsevier B.V. All rights reserved.Keywords: Cochleate cylinder; B domain deleted recombinant factor VIII; Epitope shielding; Laurdan; Protein formulation; Acrylamide quenching1. Introduction
Factor VIII (FVIII) is a multi-domain glycoprotein that
participates in the formation of the tenase complex that is central
to the blood coagulation cascade [1]. FVIII heterodimer consistsAbbreviations: aPTT, activated partial thromboplastin time; FVIII, B domain
deleted recombinant factor VIII; BPS, brain phosphatidylserine; BSA, bovine
serum albumin; ELISA, enzyme-linked immunosorbent assay; FVIII, factor
VIII; PB, phosphate buffer; PBA, phosphate buffer with 1% bovine serum
albumin; PBT, Tween 20 containing phosphate buffer; PS, phosphatidylserine;
rFVIII, recombinant human factor VIII; SDS-PAGE, sodium dodecyl sulfate-
polyacrylamide gel electrophoresis
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doi:10.1016/j.bbamem.2007.08.001of a heavy and a light chain that are held together by a divalent
metal ion [2]. The heavy chain of FVIII is heterogeneous with
molecular weight in the range of 90 to 210 kDa and comprises of
domains A1, A2 and B, connected by small peptides rich in
acidic amino acid residues [2]. The light chain of FVIII has a
molecular weight of ∼80 kDa and is comprised of domains A3,
C1 and C2. Numerous point mutations and deletion in the A or
the C domains significantly affected the biological function of
FVIII. These mutations cause hemophilia A and are clinically
manifested as hemorrhagic episodes [3]. This condition can be
corrected by exogenous administration of plasma-derived FVIII
or recombinant human FVIII (rFVIII) [4,5].
Despite the advantages of recombinant FVIII therapies,
nearly one out of three patients developed high inhibitory anti-
body titers causing difficulties in the management of the disease
[6,7]. Immunogenicity is detrimental for the use of proteins as
therapeutic agents and is governed by protein sequence, protein
aggregation and frequency of administration [8]. Previously, we
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immunogenicity compared to free rFVIII [9,10]. It has been
postulated that only four hydrophobic groups located in the C2
domain of FVIII interact with PS-containing liposomes [11] and
that a large surface area of the protein is exposed to the external
milieu [12]. Thus, rFVIII associated with liposomes results in
reduced in vivo stability, being susceptible to degradation by
proteases, following administration. Further, when administered
intravenously, non-pegylated PS-containing liposomes are
avidly taken up by RES, greatly reducing the half-life of the
cargo.
Cochleate cylinders are generated from negatively charged
PS liposomes in the presence of divalent counter ion such as
Ca2+ and are packed lipidic structures with no aqueous space
[13]. The mechanism of cochleate cylinders assumes a fusion
step mediated by Ca2+, followed by the leakage of the contents
of the liposomes. Papahadjopoulos et al. have demonstrated that
fusion of liposomes depended on the ratio of PS and Ca2+ ions
[13]. In addition, it has been reported that a threshold concen-
tration of CaCl2 of 1 mM is required for this molecular process
[13]. Small molecules as well as larger molecules can partition in
this lipidic structure, either between adjacent lipid bilayers or
within the lipid bilayer [14–16]. Thus the lipid–drug complexes
are characterized by a decreased exposure of the drug to the
solvent [14–16]. In addition, based on their increased stability
compared to other lipidic structures, such as liposomes, cochleate
cylinders emerged as novel drug delivery vehicles [14,17,18].
Here, we exploit the specific interaction between FVIII and
PS to develop FVIII-containing cochleate cylinders with de-
creased solvent exposure compared to FVIII-liposomal for-
mulations. In addition, the results indicated that cochleate
cylinders maintain the activity of FVIII and could improve the
resistance to enzymatic degradation of the protein. Furthermore,
we describe alternatives for generating cochleate cylinders with
size ranging from 200 to 600 nm that could constitute the basis
for developing novel FVIII formulations.
2. Materials and methods
2.1. Materials
Albumin-free B domain deleted rFVIII3 either was purchased fromAmerican
Diagnostica (Greenwich, CT) or obtained as a gift from the Hemophilia Center of
Western New York (Refacto, Wyeth, St. Louis, MO). Normal (control) plasma
and FVIII-deficient plasma were purchased from Trinity Biotech (Co Wicklow,
Ireland). Brain phosphatidylserine (BPS) was from Avanti Polar Lipids
(Alabaster, AL), stored in chloroform at −80 °C and used without further purifi-
cation. Laurdan (6-dodecanoyl-2-dimethylaminonaphthalene) and lissamine
(rhodamine B phosphatidylethanolamine) were purchased from Invitrogen
(Carlsbad, CA). Sterile, pyrogen-free water was acquired fromHenry Schein Inc.
(Melville, NY). Goat anti-mouse immunoglobulins conjugated to alkaline
phosphatase were from Southern Biotechnology Associates, Inc. (Birmingham,
Alabama). The monoclonal antibodies ESH4, ESH5 and ESH8 were obtained
from American Diagnostica Inc. (Greenwich, CT). The monoclonal antibody
N77210M was purchased from Biodesign International (Saco, MN). IgG-free
bovine serum albumin (BSA), trypsin, diethanolamine and acrylamide were from
Sigma (Saint Louis, MO). p-Nitrophenyl phosphate disodium salt was purchased
from Pierce (Rockford, IL). 4–15% Tris–HCl precast polyacrylamide gels were3 Note: FVIII denotes B domain deleted factor VIII.acquired from BioRad (Hercules, CA). All other buffer salts used in the study
were purchased from Fisher Scientific (Fairlawn, NJ).
2.2. Preparation of small unilamellar vesicles (SUV)
Liposomes were prepared from BPS (phase transition temperature, Tc∼6–
8 °C) as described before [19]. The required amounts of phospholipids were
dissolved in chloroform and the solvent was evaporated using a rotary evaporator
(Buchi-R200, Fisher Scientific) to form a thin lipid film. Liposomes were formed
by rehydrating the film in Ca2+-free Tris buffer (300 mM NaCl, 25 mM Tris, pH
7.0, prepared in sterile pyrogen-free water) at 37 °C. The liposome formulations
were extruded multiple times through double-stacked polycarbonate membranes
of progressively smaller pore size (400, 200, and 80 nm) using a high-pressure
extruder (Mico, Inc., Middleton, WI) operated at ∼250 psi. Lipid recovery was
estimated by assay of inorganic phosphorous using the method of Bartlett [20].
The size distribution of the liposomes was determined using a Nicomp Model
CW 380 particle size analyzer (Particle Sizing Systems, Santa Barbara, CA) as
described previously [12].
2.3. Incorporation of fluorescent probes
Fluorescent probes were incorporated by adding the required amounts of
fluorophores to the lipid mixtures, before the lipid film was formed. Laurdan was
added at a ratio of 1:1000 (Laurdan to lipid). Rhodamine–DOPE constituted
0.1% of the total lipid.
2.4. Association of FVIII with SUVs
Liposomes were associated with the appropriate amount of FVIII by
incubating at 37 °C for ∼30 min with gentle swirling. The protein to lipid
ratio was maintained at 1:10,000 for all the experiments, unless stated
otherwise.
2.5. Preparation of cochleate cylinders in aqueous buffers
Cochleate cylinders were formed from BPS-containing liposomal FVIII
preparations following addition of a stock solution of CaCl2. The final Ca
2+
concentration was 5 mM if not stated otherwise. If needed, the size of the
cochleate cylinders was controlled by subjecting the preparation to 5 cycles of
freeze–thawing by freezing in liquid nitrogen followed by thawing at room
temperature. The preparation was filtered through a 0.45-μmMillex™-GP filter
unit (Millipore Corporation, Bedford, MA) to remove larger cochleates.
2.6. Preparation of smaller cochleate cylinders in viscous buffers
Liposomal FVIII preparations were mixed with a stock solution of dextran
(MW 43 kDa) in Ca2+-free Tris buffer, to achieve a final concentration of 20%
dextran (w/v). Aliquots of CaCl2 were added to the sample in multiple steps. The
samples were mixed thoroughly after each addition of CaCl2 and incubated at
37 °C for 15 min. The final concentration of CaCl2 was approximately 2.5 mM.
The sample was diluted to approximately 5% dextran (w/v) using 2.5 mMCaCl2
containing Tris buffer.
2.7. Electron microscopy studies
Samples were prepared by coating 2 μL of solution on formvar-coated grids
and negatively staining them with 2% uranyl acetate. The grids were air dried for
5 min after addition of each reagent. The specimens were analyzed with a
Hitachi H500 TEM operating at 75 kV.
2.8. Size measurements of lipidic particles
The size of PS liposomes and small cochleate structures was measured using
dynamic light scattering (Nicomp Model CW 380 particle size analyzer, Particle
Sizing Systems, Santa Barbara, CA). For dextran-containing samples, the
viscosity of the solution was determined using a Cannon-Fenske viscometer (DC
Table 1
Capture and probe antibodies used for the Sandwich ELISA studies
Capture antibody Probe antibody
Name Epitope Coating
concentration
(μg/mL)
Source Dilution
ESH4 C2 domain
(2303–2332) [34]
5 Rat polyclonal 1:500
ESH5 Acidic region a1 [34] 5 Rat polyclonal 1:500
ESH8 C2 domain
(2248–2285) [34]
5 Rat polyclonal 1:500
N77210M A2 domain 12.5 Rat polyclonal 1:500
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extrapolated from literature data.
The size of cochleate cylinders was also measured using fluorescence
microscopy. Images of rhodamine B-labeled cochleate cylinders were acquired
on a fluorescent microscope (Zeiss photomicroscope equipped with fluorescence
optics, a Princeton Micromax CCD (Princeton Instruments, Rochester, NY) and
Ludl Electronics (Hawthorne, NY)). The major axis of various particles present
in different frames was measured and averaged to obtain a mean particle size for
cochleate cylinder preparations.
2.9. Separation of free protein from cochleate associated protein
To estimate the amount of protein associated with cochleate cylinders, free
protein was separated from cochleate-associated protein by centrifugation at
13,000×g for 5 min. Due to the low buoyancy, dehydrated cochleate cylinders
and their associated protein formed a pellet at the bottom of the tube, whereas free
FVIII remained in the supernatant. The free protein was quantified either by
activity assay or by measuring the absorbance at 280 nm. The protein associated
with the cochleate cylinders was estimated based on the difference between the
total protein and the free protein in the supernatant. The activity assay mea-
surements of free protein before and after centrifugation confirmed that protein
recovery was 100% and to ensure that all cochleate cylinders are separated under
the experimental conditions, turbidity of the samples was monitored at 320 nm
before and after centrifugation and compared to the turbidity of the protein
samples alone.
2.10. Steady-state Laurdan fluorescence spectroscopy
The emission spectra of Laurdan were acquired on a PTI fluorometer (Photon
Technology International, Lawrenceville, NJ) equipped with a Peltier unit and a
xenon arc lamp, as described before [19]. The excitation monochromator was set
to 340 nm and the fluorescence of Laurdan was monitored between 410 and
550 nm. The excitation and emission slits were set to 4 nm. The inner filter effect
was minimized by carrying out experiments in an “I”-shaped quartz cuvette [21].
Spectra of control liposomes in LC phase and in gel phase were acquired at 37 °C
and 0 °C, respectively. To account for small variations in lipid and probe
concentrations, data were normalized by plotting the F/Fmax vs. wavelength,
where F is the fluorescence intensity at any given wavelength and Fmax is the
maximum fluorescence intensity.
2.11. Steady-state protein fluorescence and acrylamide
quenching studies
Steady-state tryptophan fluorescence emission spectra were acquired on a
PTI fluorometer (Photon Technology International, Lawrenceville, NJ)
equipped with a Peltier unit and a Xe arc lamp. All samples contained 5 μg/
mL of FVIII. The protein to lipid ratio for both liposomes and cochleate
cylinders was kept constant at 1:10,000. Fluorescence spectra were acquired by
exciting the sample at 285 nm and monitoring the emission between 310 and
400 nm. The contribution from the Raman band was minimized by moving the
excitation monochromator to 275 nm. To correct for variations in protein
concentration and lamp intensity output, data were normalized by plotting the
F/Fmax vs. wavelength, where F is the fluorescence intensity at a given wave-
length and Fmax is maximum fluorescence intensity.
For acrylamide quenching experiments, the fluorescence intensity was
monitored at 330 nm following excitation at 285 nm, as described previously
[12]. Two stock solutions of 2.5 μg/mL protein and 147 μMPS lipidic structures
were prepared in Tris buffer containing 0 and 5 M acrylamide, respectively. The
stock solutions were mixed under different ratio to achieve various concentra-
tions of acrylamide. Data were analyzed using the modified Stern–Volmer
equation:
F0
F
¼ Kdd Qþ 1 ð1Þ
where F0 and F are the fluorescence intensities in the absence and presence of
acrylamide, Kd is the Stern–Volmer constant and Q is the concentration of the
acrylamide.2.12. Sandwich enzyme-linked immunosorbent assay (ELISA)
The exposure of different domains of FVIII to bulk aqueous phase was
evaluated using a sandwich ELISA experiment, as described before [22]. The
concentration of FVIII was maintained at 150 ng/mL for all ELISA experiments.
Coating of the wells was achieved by incubating the plates with 50 μL/well of
capture antibody solution (see Table 1) in carbonate buffer (Na2CO3 200 mM,
pH=9.4) for 16 h at 4 °C. The plates were washed 6 times with 100 μL of
phosphate-buffered saline (PBS: 10 mM Na2HPO4, 1.8 mM KH2PO4, 14 mM
NaCl, 2.7mMKCl, pH 7.40) containing 0.05%Tween 20 (PBT). The plates were
incubated with 200 μL/well of 1% bovine serum albumin (BSA) in PBS at room
temperature for 2 h to eliminate non-specific binding. Awashing step using PBT
was carried out prior to the incubation with 50 μL of FVIII–lipidic complexes
(150 ng/mL FVIII) in 1% BSA in PBS at 37 °C for 1 h. Following washing with
PBT, the plates were incubated in the presence of 100 μL/well of a mixture
containing rat anti-human rFVIII polyclonal antibody (1:500 dilution) and goat
anti-rat IgG-alkaline phosphatase-conjugated antibody (1:1000 dilution) in 1%
BSA in PBS at room temperature for 1 h. The washing step was performed as
described above and the plates were incubated at room temperature with 200 μL
of 1 mg/mL p-nitrophenyl phosphate solution in diethanolamine buffer (1 M
diethanolamine, 0.5 mMCaCl2). Thirty minutes later, the reaction was quenched
using 100 μL of 3 N NaOH and the optical density of the alkaline phosphatase
reaction product was determined at 405 nm using a SpectraMax plate reader
(Molecular Device Corporation, Sunnyvale, CA).
2.13. Trypsin digestion studies
Trypsin digestions of free FVIII or FVIII–cochleate cylinders complex were
carried out as described below: Twenty microliters of 10.5 μg/mL of free or
lipidic (75 μM lipids) FVIII was digested with 0.1 U of trypsin in Tris buffer
(25 mM Tris, 300 mM NaCl, 5 mM CaCl2, pH 7.4). The reaction mixture was
incubated at 37 °C for 30 min. Following addition of 10 μL of Laemmli buffer
(containing 2-mercaptoethanol), samples were incubated at 90 °C for 5 min.
28μL of each samplewas loaded on a 4–15%precast Tris–HCl gel and subjected
to electrophoresis under reducing conditions. The gel was visualized by staining
with Colloidal Blue Staining Kit (Invitrogen, Carlsbad, CA) and densitometric
scans were obtained using a Kodak Image Station (Rochester, NY).
2.14. Activity of FVIII associated with cochleate cylinders
2.14.1. In vitro activity
The in vitro activity of free- and cochleate-bound FVIII was determined by
activated partial thromboplastin time assay (aPTT) [23] and by chromogenic
assay [24]. For aPTT assay, the samples were mixed with FVIII-deficient
plasma as substrate. The clotting time was measured, following addition of
platelin L reagent and CaCl2, using a Coag-A-Mate XM coagulation analyzer
(Organon Teknika Corporation, Durham, NC). The activity of cochleate-bound
FVIII was extrapolated from a standard curve generated using rFVIII standards
(Sigma, St. Louis, MO). In order to evaluate the influence of cochleates on the
aPTT assay, control experiment containing a second set of BDDrFVIII
dilutions was prepared and cochleate cylinders were added to each diluted
sample to maintain a protein to lipid molar ratio of 1:10,000. For chromogenic
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prepared. The dilutions were also made in FVIII-free human plasma to
determine the effect of von Willebrand Factor (vWF) on the release of the
protein from cochleates. The diluted samples or standards were incubated with
factor reagent followed by chromogenic substrate. Acetic acid was added to
stop the reaction and the absorbance was measured at 405 nm. The activity of
FVIII–cochleate was determined from a standard curve created using rFVIII
standards.
2.14.2. In vivo activity
The in vivo activity of BDDrFVIII–cochleate complex was investigated
by both quantitative (blood concentrations) and by qualitative (tail clip)
methods. Six mice were given intravenous injections of 400 IU/kg of the
BDDrFVIII–cochleate complex via the penile vein. Three mice were
sacrificed 4 h post administration and their blood was collected by cardiac
puncture into syringes containing acid citrate dextrose buffer. Plasma was
separated by centrifugation at 10,000×g for 5 min at 4 °C and FVIII
activity in the plasma was measured by chromogenic assay (Coamatic
FVIII, DiaPharma Group, West Chester, OH). The remaining animals that
were given FVIII–cochleate complex were subjected to tail clip assay by
cutting 2 cm of the tails at 4 h post administration and the survival of the
animals was followed for 20 h. The rationale for performing the survival
analysis for 20-h duration is that sham-treated animals did not survive
beyond 17 h of tail clip. The surviving mice were subjected to another tail
clip at 24 h (1 cm) and monitored for survival for 24 h. At the end of
48 h, the surviving mice were sacrificed and the residual FVIII activity was
measured.
2.15. Release kinetics
10 IU/mL of FVIII–cochleate complex in RPMI 1640 media with 10%
FVIII-deficient plasma and 25 IU/mL of FVIII–cochleate complex in
calcium containing Tris buffer (300 mM NaCl, 25 mM Tris, 5 mM Ca2+, pH
7) were incubated at 4 °C (storage condition) and at 37 °C but in buffer
conditions it has been shown that incubation of FVIII at 37 °C will lead to
aggregation of protein and loss of activity [25,26]. The amount of FVIII
released from cochleates was measured after incubating for 0, 4, 8, 12, 24,
and 48 h. Samples were centrifuged at 10,000×g for 5 min at 4 °C and the
supernatant, which contains the free FVIII, was measured for its activity by
aPTT assay. Fresh media or buffer was added back into the Eppendorf tubes,
mixed well with the pellet, and placed back to their respective temperature
conditions.Fig. 1. Electron microscopy images of cochleate cylinders formed in the (A)
absence and (B) presence of FVIII, respectively. The lipid particles were
negatively stained with uranyl acetate as described in the methodology section.
The protein to lipid ratio was 1:10,000.3. Results and discussion
It has been shown that PS liposomes improved the stability
and also decreased the immunogenicity of rFVIII formulations
[27]. Since the binding of rFVIII to PS liposomes is mediated
only by interactions with the C2 domain [12], a larger fraction
of the protein surface is exposed to the external milieu, which
greatly reduces the in vivo stability of the protein. Here, we
investigated whether FVIII can be associated with cochleate
cylinders and whether these lipidic structures can decrease the
solvent exposure of both heavy and light chains that can
potentially improve the stability of FVIII in biological matrices.
3.1. Preparation and characterization of FVIII-containing
cochleate cylinders
3.1.1. Preparation of FVIII-containing cochleate cylinders
Cochleate cylinders containing FVIII were generated from
PS liposomes by Ca2+ addition method. First, FVIII was as-
sociated with PS liposomes in a buffer containing no calciumor 0.8 mM CaCl2 (below threshold calcium concentration of
1mM required for the formation of cochleates and vesicle
fusion) and 300 mMNaCl. The morphology of the particles was
investigated by TEM. The particles displayed typical lamellarity
characterized by a donut-like structure. In the second step, PS
liposomal FVIII was fused to form cochleate cylinders by in-
creasing the concentration of CaCl2 to 5 mM. Particles gen-
erated by this method were investigated by TEM. Cylindrical
shape particles were observed for samples both in the presence
and in the absence of protein (Fig. 1), consistent with published
results for cochleate cylinders [19]. As clear from the figure, the
morphology of particles was similar suggesting that FVIII does
not affect the formation of cochleate cylinders.
Free (unassociated) FVIII was separated from the FVIII-
bound cochleate cylinders by centrifugation and the activity
assay indicated that approximately 75±12% (mean±S.D., n=5)
of FVIII was bound to cochleate cylinders and that the protein
retained its activity. It is appropriate to mention here that for
conventional liposomes (DMPC/BPS: 70:30) approximately
40% of FVIII bound to the outer leaflet of the membrane [12],
further suggesting the advantage of cochleate cylinders to
encapsulate approximately twice as much FVIII than conven-
tional liposomes.
Fig. 2. Fluorescent microscopy of rhodamine B-labeled cochleate cylinders in
the (A) absence and (B) presence of FVIII. The rhodamine B to lipid ratio was
1:1000 and the protein to lipid ratio was 1:10,000.
Fig. 3. Normalized fluorescence emission spectra of Laurdan-labeled lipidic
particles. Spectra are shown for cochleate cylinders in the presence (grey solid
line) and absence of FVIII (black solid line). The typical spectra of Laurdan in
liposomes either in the gel phase (black dashed line) or in the liquid crystalline
phase (grey dashed line) are also shown for comparison. All sampleswere excited
at 340 nm and the fluorescence was monitored between 420 and 550 nm.
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of FVIII, one-stage aPTT assay measurements were performed.
The activity of free or cochleate-bound FVIII was expressed as
percentage of the initial protein activity and the data indicated
that the protein retained its activity following association with
cochleate cylinders. In the presence of cochleates, coagulation
times were delayed marginally at all corresponding FVIII dilu-
tions studied. Furthermore, the cochleate-bound protein did not
display any activity when measured by chromogenic assay. It is
not clear how the activity of the protein is measurable by one-
stage assay but not by chromogenic assay. It is possible that the
assay conditions for apTT, such as presence of activator or he-
mophilic plasma/vWF may trigger the release of the protein but
for chromogenic assay, the protein that is packed inside the
particle may not be available for the activity assay. In order to
determine that presence of plasma/vWF initiates the release of
the protein, the chromogenic assay was performed in the pre-
sence of FVIII-deficient human plasma. The results showed that
in the presence of plasma, FVIII activity was detectable
suggesting that plasma components/vWF possibly triggers the
release of the protein.
3.1.2. Characterization of FVIII-containing cochleate cylinders
Due to the geometry of cochleate cylinders, the size of the
particles in the presence and the absence of FVIII was invest-igated using fluorescence microscopy rather than by dynamic
light scattering (DLS).
PS-containing liposomes were labeled with rhodamine B–
dioleoyl phosphatidylethanolamine by incorporating 0.1 mol%
of fluorescent probe in the lipid bilayer as described in the
Materials and methods section. Addition of CaCl2 resulted in
formation of particles with elongated shapes (Fig. 2A and B),
consistent with the TEM images for cochleate cylinders (Fig. 1).
The major axes of different cochleate cylinders were measured
to obtain the size distribution of the particles. The size of par-
ticles is in the range of 0.8 to 5.5 μm with an averaged size of
2.8±1.6 μm and 2.5±1.5 μm (mean±S.D., n=12) in the ab-
sence and presence of FVIII, respectively. The results indicate
that FVIII does not alter the size of cochleate cylinders. It is
appropriate to mention that due to the physical limitations of the
optics of the microscope (40× objective), free probe or fluo-
rescent-labeled PS liposomes were not detectable and do not
interfere with the size measurement of the cochleate cylinders.
We further investigated the morphology of cochleate cylin-
ders through Laurdan spectroscopy. Based on its localization at
the interface between the polar glycerol head group and the acyl
chains of phospholipids, Laurdan (6-dodecanoyl-2-dimethyla-
mino naphthalene) is sensitive to the polarity of the surrounding
environment [28,29]. The Laurdan spectra of PS liposomes and
cochleate cylinders in the presence and absence of the protein are
shown in Fig. 3. At 0 °C, in the absence of CaCl2, Laurdan
spectrum of FVIII-associated liposomes was characterized by a
fluorescent peak maxima at∼430 nm (Fig. 3), a typical Laurdan
profile for liposomes in the gel phase. A second peak at 490 nm
was observed for the Laurdan-labeled liposomes when the
temperature was increased to form the liquid crystalline phase
(Fig. 3), suggesting that the reorganization of water molecules
could transiently stabilize the ground state of Laurdan [28]. A
decrease in the intensity at 490 nm and a blue shift in the band at
430 nm were observed for the spectrum of Laurdan in cochleate
cylinders [19], suggesting that the ground state of the probe was
not stabilized by dipolar interactions with the solvent. Those
observations were consistent with the dehydrated environment
of the cochleate cylinders. The spectral properties of Laurdan
incorporated in cochleate cylinders in the presence and absence
Fig. 5. Solvent accessibility of individual domains of FVIII in Sandwich ELISA.
Capture antibodies are shown in the figure legend. For each capture antibody, the
binding to the free protein was considered to represent 100% binding. The
concentration of FVIII was maintained constant in all the preparations tested.
Vertical bars represent the mean %antibody binding and the error bars represent
S.D. (n=3).
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substantially affect the packing of lipids in cochleate cylinders.
3.2. Generation and characterization of small cochleate cylinders
Generation of small cochleate cylinders would be ideal for the
parenteral delivery of FVIII. Two different approaches were
investigated for the formation of small cochleate cylinders. The
first approach was designed based on freeze–thaw cycling of
cochleate cylinders. Small particles generated by five freeze–
thaw cycles were separated by filtration through a 0.45-μm filter.
Since multiple freeze–thaw cycles have been shown to decrease
the activity of FVIII, a second approach was designed to control
the size of cochleate cylinders. Here, we controlled the growing
rate of cylinders, rather than breaking them in smaller particles.
We limited the diffusion rate of the PS liposomes by adding
concentrated dextran solutions into the sample. Particles gene-
rated by these two methods have a mean size of∼500 nm or less
and share Laurdan spectral characteristics typical of cochleate
cylinders (data not shown).
3.3. Conformation of protein associated with cochleate cylinders
Intrinsic fluorescence spectroscopy is a reliable tool in asses-
sing the tertiary structural details of proteins [21]. To investigate
the effect of cochleate cylinders on the tertiary structure of FVIII,
fluorescence spectra were acquired for free-, liposome-bound
and cochleate-bound FVIII, respectively. Typical fluorescence
spectra of FVIII in the presence and absence of lipidic particles
were shown in Fig. 4. As can be clearly seen in the figure, the
intrinsic fluorescence for free FVIII was characterized by a peak
maxima of∼331 nm and the addition of liposomes did not result
in spectral changes, suggesting that association of the protein
with liposomes did not alter the tertiary structure of the protein.
This is due to the fact that only a small portion of the protein is
involved in lipid interactions and is consistent with previous
results [12]. A blue shift in peak maximum from 331 nm toFig. 4. Trp intrinsic fluorescence spectra for free-, liposomal- and cochleate-
bound FVIII. The excitation wavelength was set for 285 nm and the fluorescence
emission spectra were recorded between 310 and 400 nm. The protein con-
centration was of 5 μg/mL and the protein to lipid ratio was of 1:10,000.327 nm was observed for cochleate cylinders. The substantial
blue shift in the peak maxima and the increase in intrinsic fluo-
rescence intensity (data not shown) indicated that the microen-
vironment surrounding FVIII was more hydrophobic in the
presence of cochleate cylinders compared to either liposomal or
free FVIII
3.4. Topology of FVIII bound to cochleate cylinders
Sandwich ELISA studies were carried out to investigate the
domains/epitopes involved in the interactions with cochleate
cylinders. The rationale for this experiment is that the anti-FVIII
antibodies will not have access to the epitopes that are shielded
by the cochleate structures and thus would allow to investigate
the topology of FVIII–cochleate structures. The capture
antibodies were chosen to investigate the involvement of several
domains. For convenience, their names and the epitope recog-
nized are listed in Table 1. Binding to the free protein was
normalized to 100% to compensate for the differences between
affinity constants of different antibodies (Fig. 5). For the
protein–liposomal complex, the antibody binding to FVIII
decreased from 38.8±3.0% (N77210M) to 32.4±1.2% (ESH5),
26.2±0.7% (ESH8) and 3.0±2.6% (ESH4) (mean±S.D., n=3),
suggesting that only the epitope recognized by ESH4 in the C2
domain was efficiently shielded by the liposomes, in agreement
with previous results [12]. In contrast, for the cochleate cylinder
complex, binding of antibody recognizing both heavy and light
chain decreased significantly, suggesting that both chains are
shielded by the lipidic structures.
The solvent exposure of FVIII bound to cochleate cylinders
was further confirmed by acrylamide fluorescence quenching
experiments. Acrylamide is a collisional quencher that has been
extensively used to investigate the exposure of Trp residues to
the external milieu [12,30]. The efficiency of acrylamide quen-
ching is dependent on the frequency of collisions between the
quencher and the fluorophore and is proportional to the Stern–
Volmer constant, Kd (Eq. (1), Materials and methods and Ref.
Fig. 6. Acrylamide quenching of the fluorescence of free FVIII and lipidic FVIII
formulations. Data were plotted asF0/F as a function of acrylamide concentration
and fitted by linear regression to obtain the Stern–Volmer constant for acrylamide
quenching (Kd). Samples were excited at 285 nm and the emissionwasmonitored
at 330 nm. The protein concentration was 2.5 μg/mL in all acrylamide quenching
experiments.
Fig. 7. Densitometric scan analysis of the SDS-PAGE for free- and cochleate-
bound FVIII in the presence and absence of trypsin. Enzymatic digestion studies
were carried out using 0.1 U of trypsin for 30 min at 37 °C.
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the quencher will not have access to Trp residues and no change
in protein fluorescence intensity should be observed. Addition of
increasing concentrations of acrylamide to the free protein in
solution quenched the Trp fluorescence (Kd=14.6 M
−1). The
quenching was less for liposomal FVIII than for the free protein
(Kd=8.9 M
−1), in line with the observations by Purohit et al.
[12] that only a few numbers of Trp residues located in the light
chain were properly shielded by the liposomal membrane. As
shown in Fig. 6, the Kd value for the quenching of the Trp
residues of FVIII bound to cochleate cylinders (Kd=4.0 M
−1)
was more than 50% smaller than the Kd value for liposomal
FVIII. The data clearly showed that the change in Kd value
between the two lipidic formulations indicated that the exposure
of the protein to the aqueous milieu was decreased for cochleate-
bound FVIII compared to liposomal-bound FVIII.
3.5. Stability of FVIII in the presence of proteolytic enzymes
Proteoyltic degradation in biological matrices has been pro-
posed to be the major route of elimination for therapeutic pro-
teins. Trypsin is an efficient protease that has been extensively
used for protein digestion in proteomics and mass spectrometry
applications [31–34]. To investigate if FVIII bound to cochleate
cylinders has increased stability compared to free FVIII, we
performed enzymatic digestion studies in the presence of try-
psin. Free- and cochleate cylinder-bound FVIII were subjected
to proteolysis using 0.1 U of enzyme for 30 min. The digestion
products, as well as free- and cochleate-bound FVIII, were
characterized by SDS-PAGE. The densitometric scan of the
polyacrylamide gel is shown in Fig. 7. Three polypeptide bands
were identified for either free- or cochleate-bound FVIII in the
absence of trypsin. The 80-kDa polypeptide corresponds to the
light chain. The 90-kDa polypeptide was attributed to the heavy
chain that lacks the B domain. The 170-kDa polypeptide bandcorresponds to the uncleaved single chain precursor of
BDDrFVIII. Digestion of the free protein leads to generation
of smaller peptide with molecular weight ranging from 15 to
70 kDa (Fig. 7). Neither the 80-kDa nor the 90-kDa band was
visible in the densitometric scan, suggesting that both heavy
and light chains of free FVIII were efficiently digested by the
enzyme. In contrast, the digestion of cochleate-bound FVIII
complex resulted in a different pattern of bands. As shown in the
densitometric scan, both intact heavy (90 kDa) and light
(80 kDa) chains as well as the single chain precursor (170 kDa)
were visible, suggesting that cochleate cylinders prevented en-
zymatic degradation of FVIII. However, peptides with molec-
ular weight ranging from 15 to 70 kDa were also observed,
indicating that enzymatic digestion was observed to a smaller
extent.
Our ELISA, acrylamide quenching and enzymatic digestion
studies demonstrated that the exposure of FVIII to the aqueous
phase is reduced in the presence of cochleate cylinders,
compared to free and liposomal protein. This reduced solvent
exposure can be explained only if both heavy and light chains of
FVIII are buried either in the lipid bilayer or in between adjacent
lipid bilayers of cochleate structures and substantial surface area
of FVIII molecule is shielded from bulk aqueous compartment.
3.6. Release kinetics
The topology studies suggested that substantial surface area
of the protein is shielded by the cochleates implying that there is
potential increase in in vivo stability. Cochleate cylinders have
been used as delivery vehicles to improve the efficacy of thera-
peutic agents [17,18]. However, the release of the protein from
the cochleates for extended period of time is key to realize the
effectiveness of the delivery vehicle. FVIII that released from the
cochleates in Ca2+ containing buffer and in RPMI 1640 media
Fig. 8. In vitro release kinetics study of FVIII–cochleate complex. 25 IU of FVIII
was associated with the cochleate and the release of protein was investigated until
48 h at 4 °C in Ca2+ containing Tris buffer.
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of sample incubation at 4 °C or 37 °C. In case of the RPMI 1640
media containing 10% FVIII-deficient plasma, immediate
clotting was observed possibly due to co-existence of calcium,
activator and other clotting factors from the deficient plasma,
which may have triggered the release of the protein. To resolve
this issue, RPMI 1640 media containing 10% FVIII-deficient
plasma were substituted with calcium containing Tris buffer in
the study (Fig. 8). No clotting was observed at 0 h suggesting
that there was no release of FVIII from the complex and that
most of the FVIII was associated with the cochleates.
Approximately 24% of FVIII was released after incubation for
4 h at 4 °C. After 12 h, amount of FVIII released reached a
plateau and the cumulated FVIII released at 48 hwas 7.68 IU/mL
at 4 °C compared to initial concentration of 25 IU. The data
suggested that the release of the protein from the particle is slow
and sustained. Furthermore, in vivo, the release of the protein
from the particle may also be triggered by several other
mechanisms including the degradation of the particle and by
the binding of the particle to complement proteins [35].
3.7. In vivo study
Due to the targeted deletion of exon 16 of the FVIII gene, the
hemophilic mice do not express any active FVIII molecules [36].
Thus, any sustained injury results in prolonged bleeding and
possibly the death of the animals. Therefore this animal model
would be useful to test the efficacy of FVIII preparations as any
clotting observed would be that of exogenously administered
FVIII. The in vivo efficacy of the FVIII–cochleate complex was
determined both quantitatively (plasma concentrations) and
qualitatively (tail clip assay) to evaluate the dose–response
relationship. Following intravenous administration of the 10 IU
per animal of FVIII–cochleate complex, we collected blood and
also performed tail clip experiment by cutting 2 cm of the tail at
4 h and 1 cm at 24 h post administration. The activity of the
protein measured by chromogenic assay showed that the blood
concentration of FVIII in the mice at 4 h post-injection of the
FVIII–cochleate complex was 2.0±0.3 IU (mean±S.D., n=3).
Since the cochleate-associated protein did not show any activityas measured by chromogenic assay, the blood concentration
detected would be that of free protein (released from the
particle). Overall, the data suggest that in in vivo conditions, the
protein is released from the particle and we speculate that several
factors would have contributed for the release including the
degradation of the particle and/or its binding to complement
proteins [34] or the binding affinity of FVIII to vWF, as sug-
gested by the in vitro studies.
The activity of FVIII detected for cochleate treatment group
is less than that observed for animals given free FVIII in which
4.2±1.4 IU (mean±S.D., n=3) of the protein was detected after
4 h of administration. This difference would account for the
amount of FVIII that are still associated with the cochleates (as
the cochleate associated protein could not be detected by
chromogenic activity assay) and also the protein eliminated
through lipid particulate uptake by RES. Detailed pharmacoki-
netic study is in progress to address this issue. Nevertheless, the
tail clip assay showed that the bleeding stopped in all the animals
that received FVIII–cochleate preparations, indicating that
FVIII–cochleate complex is effective in vivo and protects the
hemophilic mice from excessive bleeding.
4. Conclusions
In conclusion, FVIII–lipidic cochleate structures were gene-
rated in which both heavy and light chains were properly
shielded from the bulk aqueous phase. In addition, FVIII asso-
ciated with cochleate cylinders retained biological activity. The
data demonstrated that it is possible to develop FVIII complexed
in novel cochleate cylinders for protein delivery applications.
However, a detailed pharmacokinetic study is necessary to
clearly understand the efficacy of the FVIII–cochleate complex.
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